Show simple item record

dc.contributor.authorGorog, Diana
dc.date.accessioned2019-04-23T14:05:32Z
dc.date.available2019-04-23T14:05:32Z
dc.date.issued2018-05-01
dc.identifier.citationGorog , D 2018 , ' Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications ' , Journal of Thrombosis and Thrombolysis , vol. 45 , no. 4 , pp. 593-602 . https://doi.org/10.1007/s11239-018-1641-2
dc.identifier.issn0929-5305
dc.identifier.otherPURE: 16605235
dc.identifier.otherPURE UUID: 8881cbf3-105c-480e-845b-4f5d13058338
dc.identifier.otherScopus: 85044048390
dc.identifier.urihttp://hdl.handle.net/2299/21293
dc.description© The Author(s) 2018
dc.description.abstractThe stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis. There is ample evidence from both laboratory and clinical studies to suggest that in addition to inhibiting platelet aggregation, antithrombotic medications have shear-dependent effects, potentiating thrombus fragility and/or enhancing endogenous fibrinolysis. Such shear-dependent effects, potentiating the fragility of the growing thrombus and/or enhancing endogenous thrombolytic activity, likely contribute to the clinical effectiveness of such medications. It is not clear how much these effects relate to the measured inhibition of platelet aggregation in response to specific agonists. These effects are observable only with techniques that subject the growing thrombus to arterial flow and shear conditions. The effects of antithrombotic medications on thrombus stability and ways of assessing this are reviewed herein, and it is proposed that thrombus stability could become a new target for pharmacological intervention.en
dc.format.extent10
dc.language.isoeng
dc.relation.ispartofJournal of Thrombosis and Thrombolysis
dc.titlePotentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medicationsen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionBasic and Clinical Science Unit
dc.description.statusPeer reviewed
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.1007/s11239-018-1641-2
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record